US4510150A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Pharmaceutical compositions effective against coronary heart disease and hypertension
Assignee: Novartis AG
•
Filing: 1983-08-01
•
Granted: 1985-04-09
•
Expires: 2003-08-01
Abstract
Abstract Pharmaceutical composition containing as active agents (A) a calcium antagonist of a 4-(2,1,3-benz-oxa- or thiadiazoly)-1,4-dihydro pyridine type and (B) a beta -blocker and/or a vasodilating nitrate, effective against coronary heart disease and hypertension.
Inventors
- 👤 Richard Berthold
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 02:15
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/44; A61P; A61P25/00; A61P25/02; A61P9/00; A61P9/12
Claims Analysis
Total Claims: 20
Claim 1
Independent Claim
80 words
A pharmaceutical composition useful in treating coronary heart disease or hypertension comprising a pharmaceutically acceptable carrier or diluent and as the active agents: (1) as component (A), a member selected from the group consisting of 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylic acid diethylester, 4-(2,1,3-benzothiadiazole-4-yl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylic acid dimethylester and 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-3-isopropyloxy carbonylpyridine-5-carboxylic acid methyl ester; and (2) as component (B), a β-adrenoceptor blocking agent possessing some degree of intrinsic sympathomimetic activity, the sum of components (A) and (B) in said composition being present in a therapeutically effective amount.
Claim 2
Dependent Claim
80 words
A pharmaceutical composition useful in treating coronary heart disease or hypertension comprising a pharmaceutically acceptable carrier or diluent and as the active agents: (1) as component (A), a member selected from the group consisting of 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylic acid diethylester, 4-(2,1,3-benzothiadiazole-4-yl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylic acid dimethylester and 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-3-isopropyloxy carbonylpyridine-5-carboxylic acid methyl ester; and (2) as component (B), a β-adrenoceptor blocking agent possessing some degree of intrinsic sympathomimetic activity, the sum of components (A) and (B) in said composition being present in a therapeutically effective amount.
Claim 3
Dependent Claim
16 words
A composition of claim 1 containing as component (A), 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylic acid diethylester or 4-(2,1,3-benzothiadiazole-4-yl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylic acid dimethylester.
Claim 4
Dependent Claim
13 words
A composition of claim 1 containing as component (B), 4-(2-hydroxy-3-isopropylaminopropoxy)indole (Pindolol) or 4-(2-benzoyloxy-3-tert-butylaminopropoxy)-2-methylindole.
Claim 5
Dependent Claim
12 words
A composition of claim 2, containing as a component (A) 4-(2,1,3-Benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylic acid-diethylester.
Claim 6
Dependent Claim
14 words
A composition of claim 1 containing as component (A), 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-3-isopropyloxy carbonylpyridine-5-carboxylic acid methyl ester.
Claim 7
Dependent Claim
13 words
A composition of claim 2 containing as component (A), 4-(2,1,3-benzothiadiazole-4-yl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylic acid dimethyl ester.
Claim 8
Dependent Claim
11 words
A composition of claim 3, containing as a component (B) Pindolol.
Claim 9
Dependent Claim
21 words
A composition of claim 1, wherein the weight ratio of components (A) and (B) is from about 100:1 to about 1:10.
Claim 10
Dependent Claim
20 words
A composition of claim 1, consisting of 4(2,1,3-Benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylic acid diethylester as a component (A) and Pindolol as a component (B).
Claim 11
Dependent Claim
21 words
A composition of claim 9, wherein the weight ratio of components (A) and (B) is from about 10:1 to about 1:10.
Claim 12
Independent Claim
84 words
A method of treating coronary heart disease or hypertension which comprises administering to a subject in need of such treatment a composition comprising as the active agents: (1) as component (A), a member selected from the group consisting of 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylic acid diethylester, 4-(2,1,3-benzothiadiazole-4-yl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylic acid dimethylester and 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-3-isopropyloxy carbonylpyridine-5-carboxylic acid methyl ester; and (2) as component (B), a β-adrenoceptor blocking agent possessing some degree of intrinsic sympathomimetic activity, the sum of components (A) and (B) in said composition being present in a therapeutically effective amount.
Claim 13
Independent Claim
84 words
A method of treating coronary heart disease or hypertension which comprises administering to a subject in need of such treatment a composition comprising as the active agents: (1) as component (A), a member selected from the group consisting of 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylic acid diethylester, 4-(2,1,3-benzothiadiazole-4-yl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylic acid dimethylester and 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-3-isopropyloxy carbonylpyridine-5-carboxylic acid methyl ester; and (2) as component (B), a β-adrenoceptor blocking agent possessing some degree of intrinsic sympathomimetic activity, the sum of components (A) and (B) in said composition being present in a therapeutically effective amount.
Claim 14
Dependent Claim
17 words
A method of claim 11 wherein the component (A) is 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylic acid diethylester or 4-(2,1,3-benzothiadiazole-4-yl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylic acid dimethylester.
Claim 15
Dependent Claim
13 words
A method of claim 11 wherein component (B) is 4-(2-hydroxy-3-isopropylaminopropoxy)indole (Pindolol) or 4-(2-benzoyloxy-3-tert-butylaminopropoxy)-2-methylindole.
Claim 16
Dependent Claim
14 words
A method of claim 11 wherein component (A) is 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-3-isopropyloxy carbonylpyridine-5-carboxylic acid methyl ester.
Claim 17
Dependent Claim
13 words
A method of claim 12 wherein component (A) is 4-(2,1,3-benzothiadiazole-4-yl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylic acid dimethyl ester.
Claim 18
Dependent Claim
10 words
A composition of claim 3 containing as component (B), 4-(2-benzoyloxy-3-tert-butylaminopropoxy)-2-methylindole.
Claim 19
Dependent Claim
10 words
A method of claim 13 wherein component (B) is 4-(2-hydroxy-3-isopropylaminopropoxy)indole.
Claim 20
Dependent Claim
10 words
A method of claim 13 wherein component (B) is 4-(2-benzoyloxy-3-tert-butylaminopropoxy)-2-methylindole.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1988-04-08 | 1988-10-08 | 1989-04-09 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1992-04-08 | 1992-10-08 | 1993-04-09 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1996-04-08 | 1996-10-08 | 1997-04-09 | $7700.00 | Window Closed / Lapsed |